KOD vs. IPHA, INMB, ADVM, ABOS, ZURA, IPSC, OPT, CGEN, ELEV, and CMPX
Should you be buying Kodiak Sciences stock or one of its competitors? The main competitors of Kodiak Sciences include Innate Pharma (IPHA), INmune Bio (INMB), Adverum Biotechnologies (ADVM), Acumen Pharmaceuticals (ABOS), Zura Bio (ZURA), Century Therapeutics (IPSC), Opthea (OPT), Compugen (CGEN), Elevation Oncology (ELEV), and Compass Therapeutics (CMPX). These companies are all part of the "biological products, except diagnostic" industry.
Kodiak Sciences (NASDAQ:KOD) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, community ranking, risk, valuation, analyst recommendations, dividends, earnings and profitability.
Innate Pharma's return on equity of 0.00% beat Kodiak Sciences' return on equity.
Kodiak Sciences currently has a consensus price target of $5.50, suggesting a potential upside of 52.35%. Innate Pharma has a consensus price target of $9.75, suggesting a potential upside of 285.38%. Given Innate Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Innate Pharma is more favorable than Kodiak Sciences.
Kodiak Sciences has a beta of 2.25, suggesting that its stock price is 125% more volatile than the S&P 500. Comparatively, Innate Pharma has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500.
In the previous week, Innate Pharma had 3 more articles in the media than Kodiak Sciences. MarketBeat recorded 4 mentions for Innate Pharma and 1 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 1.89 beat Innate Pharma's score of 0.47 indicating that Kodiak Sciences is being referred to more favorably in the media.
Innate Pharma has higher revenue and earnings than Kodiak Sciences.
89.1% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 0.2% of Innate Pharma shares are owned by institutional investors. 45.3% of Kodiak Sciences shares are owned by insiders. Comparatively, 31.9% of Innate Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Innate Pharma received 20 more outperform votes than Kodiak Sciences when rated by MarketBeat users. Likewise, 54.29% of users gave Innate Pharma an outperform vote while only 28.13% of users gave Kodiak Sciences an outperform vote.
Summary
Innate Pharma beats Kodiak Sciences on 9 of the 13 factors compared between the two stocks.
Get Kodiak Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for KOD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KOD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kodiak Sciences Competitors List
Related Companies and Tools
